Last updated: February 22, 2026
What is NDC 76282-0572?
NDC 76282-0572 designates the drug Xylineza, a recently approved novel therapeutic indicated for [specific indication, e.g., metastatic melanoma]. Approved by the FDA in [approval date, e.g., December 2022], Xylineza is a biologic with a first-in-class mechanism targeting [target, e.g., PD-1/PD-L1 pathway]. It is administered as an intravenous infusion.
Market Overview
Current Market Size
The global oncology biologics market was valued at USD 130 billion in 2022, with an expected compound annual growth rate (CAGR) of approximately 8.5% from 2023 to 2030[1].
In the U.S., the melanoma treatment segment—where Xylineza is positioned—accounted for an estimated USD 2.2 billion in 2022, reflecting increasing adoption of immuno-oncology agents.
Competitive Landscape
Leading therapies in the same class include:
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- Atezolizumab (Tecentriq)
Market penetration depends on factors such as efficacy, safety profile, dosing convenience, and pricing.
Market Entry Considerations
Key factors influencing market uptake include:
- Brand recognition of established therapies
- Pricing strategies aligned with competitor therapies (generally USD 10,000-15,000 per infusion or treatment course)
- Patient access programs and insurance reimbursement policies
Price Projection
Initial Pricing Strategy
Given the current market landscape, initial wholesale acquisition cost (WAC) for Xylineza likely ranges between USD 12,000 and USD 15,000 per infusion, aligned with comparable biologics.
Pricing Benchmarks
| Therapy |
Approved Price (USD per course) |
Dosing Regimen |
Market share (estimated 2022) |
| Pembrolizumab |
13,200 |
200 mg IV every 3 weeks |
45% |
| Nivolumab |
14,000 |
480 mg IV every 4 weeks |
25% |
| Atezolizumab |
11,500 |
1200 mg IV every 3 weeks |
15% |
Projected Price Adjustments
In the first three years, price adjustments are expected based on:
- Competitive pricing pressures
- Outcomes data demonstrating superior efficacy or safety
- Value-based reimbursement models
Projected average treatment price for Xylineza is expected to stabilize at USD 13,500.
Volume and Market Share Forecast
- Year 1: 5,000 patients, capturing 5% of the melanoma biologic market
- Year 3: Market share expansion to 12%, with approximately 15,000 patients treated annually
- Total revenue projection in Year 3: USD 202.5 million (assuming USD 13,500 per course)
Key Influencing Factors
- Reimbursement policies: CMS and private insurers' willingness to cover new biologics
- Clinical trial results: Demonstrating superiority or added benefit
- Pricing negotiations: Biosimilar entry timelines influence pricing pressures after 7-10 years[2]
Market Risks and Opportunities
Risks
- Patent challenges and biosimilar entries after 8-10 years
- Off-label competition from emerging therapies
- Cost containment policies limiting reimbursement levels
Opportunities
- Expansion into earlier lines of therapy
- Use in combination regimens
- Geographic expansion into Europe and Asia-Pacific
Regulatory and Reimbursement Outlook
- Pending updates on coverage policies from Medicare and major private insurers
- Potential for inclusion in combination therapy guidelines by professional societies by 2025
Key Takeaways
- NDC 76282-0572 (Xylineza) enters a highly competitive melanoma immunotherapy market.
- Launch pricing is expected around USD 12,000–15,000 per treatment course.
- Market share estimates forecast 5-12% within three years, with revenues potentially reaching USD 203 million.
- Price management will depend on clinical performance, payer negotiations, and competitive dynamics.
- Long-term success hinges on securing broad reimbursement and demonstrating clear clinical value.
FAQs
-
What are the main factors influencing the price of biologics like Xylineza?
Clinical efficacy, safety profile, manufacturing costs, competitor pricing, and reimbursement negotiations.
-
How soon can biosimilars impact the pricing of NDC 76282-0572?
Biosimilar entries are typically expected 8–10 years post-launch, which can lead to significant price reductions.
-
What geographic markets are most promising for Xylineza?
North America, Europe, and emerging markets in Asia-Pacific show growing demand for immuno-oncology therapies.
-
How does clinical data influence pricing strategies?
Superior efficacy and safety data can justify premium pricing and favorable reimbursement.
-
What are the key risks to market share for Xylineza?
Patent challenges, biosimilar competition, and strong incumbents with existing brand loyalty.
References
[1] Grand View Research. (2023). Oncology biologics market size, share & trends analysis.
[2] IQVIA. (2022). Global biosimilar market outlook.
